Abstract
Objectives The control of solid tumors by drug-eluting beads has been recognized in clinical practice, but there are still few applications regarding drug‐eluting beads bronchial arterial chemoembolization (DEB‐BACE) in lung cancer. To further investigate the role of DEB-BACE in patients with lung cancer. We evaluated the efficacy and safety of Pirarubicin-loaded CalliSpheres beads in patients treated for advanced non-small cell lung cancer (NSCLC). MethodsFrom June 2017 to January 2018, 54 patients with advanced NSCLC received DEB‐BACE with Pirarubicin‐loaded CalliSpheres® beads. After the treatment, the progression-free survival (PFS) and overall survival (OS) were analyzed. Moreover, adverse events and complications were also reported. ResultsAfter DEB‐BACE treatment, most of the adverse events and complications were CTCAE grade 1 or 2 (mild symptoms, no or local/noninvasive intervention indicated) . Of the 54 patients, 2 persons (4%) had grade-3 lung abscess and required percutaneous drainage, 1(2%) had a grade-3 pulmonary infection that caused difficulty breathing and required intravenous antibiotics and ventilator adjuvant therapy. Moreover, the patient’s mean PFS was 7.828 months (95% CI: 6.614, 9.043), and the mean OS rates were 17.678 months (95% CI: 15.573, 19.783). Additionally, both univariate and multivariate cox regression indicated that the disease stage (stage III) seems related to better PFS in patients with advanced NSCLC (P=0.013). ConclusionsThe clinical effect of DEB‐BACE with Pirarubicin‐loaded CalliSpheres® beads on advanced NSCLC is probably significant and could improve the PFS, the adverse events and complications were tolerable.
Advanced-stage hepatocellular carcinoma with portal vein thrombosis: conventional versus drug-eluting beads transcatheter arterial chemoembolization
